A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer

Gefitinib has shown modest activity in patients with recurrent non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. However, the activity of gefitinib as first-line chemotherapy remains unclear, especially unknown in elderly patients. A multicenter phase II trial was conducted to ev...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of thoracic oncology Vol. 3; no. 10; p. 1166
Main Authors:	Ebi, Noriyuki, Semba, Hiroshi, Tokunaga, Sho J I, Takayama, Koichi, Wataya, Hiroshi, Kuraki, Takashige, Yamamoto, Hidehiko, Akamine, Shin J I, Okamoto, Isamu, Nakanishi, Yoichi
Format:	Journal Article
Language:	English
Published:	United States 01-10-2008
Subjects:	Adenocarcinoma - drug therapy Adenocarcinoma - secondary Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Carcinoma, Large Cell - drug therapy Carcinoma, Large Cell - secondary Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - secondary Female Health Surveys Humans Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Maximum Tolerated Dose Neoplasm Staging Prognosis Quality of Life Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Survival Rate Treatment Outcome
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Gefitinib has shown modest activity in patients with recurrent non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. However, the activity of gefitinib as first-line chemotherapy remains unclear, especially unknown in elderly patients. A multicenter phase II trial was conducted to evaluate the efficacy and tolerability of gefitinib for elderly patients with chemotherapy-naïve NSCLC. Elderly chemotherapy-naïve patients with advanced NSCLC, ECOG PS of 0-2, and adequate organ functions received 250 mg/day of gefitinib. The primary objective of this study was to determine the objective response rate (RR). Secondary endpoints were tolerability, disease-related symptom using lung cancer subscale (LCS) in FACT-L, progression free survival (PFS) and overall survival (OS). We investigated mutation status of the epidermal growth factor receptor (EGFR) gene in cases with available tumor samples. Fifty patients were enrolled, of whom 49 were eligible. Median age (range) was 80 (75-90) years. Thirty-two patients were female (65%) and 40 patients had adenocarcinoma (82%). The objective RR was 25% (CI 95%, 13-39). Median survival time was 10 months (CI 95%, 7-20) and 1-year survival rate was 50%. The most frequent adverse events were skin disorders (76%). Fifteen patients (30%) experienced toxicities >/=grade 3. There were four patients with possible interstitial lung disease including two treatment-related deaths. Symptom improvement rate using LCS was 49% at 4 weeks of gefitinib therapy. Tumor samples from 17 patients were analyzed for EGFR mutation status. EGFR mutations were detected in tumor tissues from 7 patients, of which 5 had partial responses (71%). Gefitinib monotherapy is effective and relatively well tolerated in chemotherapy-naïve elderly patients with advanced NSCLC. Gefitinib has potential as a first-line therapeutic option in elderly patients with advanced NSCLC.
ISSN:	1556-1380
DOI:	10.1097/JTO.0b013e318186a88d